Short Interest in Monte Rosa Therapeutics Rises 22.2%

Shares of the biotech company see increased short selling activity

Apr. 16, 2026 at 8:50pm

Got story updates? Submit your updates here. ›

An extreme close-up of the inner workings of a complex financial machine, with gears, circuits, and other industrial components filling the frame, conceptually representing the institutional infrastructure behind short selling and stock trading.The intricate gears and mechanisms of the financial system that facilitate short selling activity on biotech stocks like Monte Rosa Therapeutics.Cambridge Today

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) saw a significant increase in short interest during March, with the number of shares sold short rising 22.2% to 13,398,925. This represents about 18% of the company's total shares outstanding. The rise in short interest comes as the biotech firm continues to advance its AI-driven drug discovery platform.

Why it matters

The increase in short interest suggests some investors are betting against Monte Rosa's stock performance, potentially signaling concerns about the company's progress or future outlook. Short selling activity can influence a stock's price and trading volume, so the rise in short interest is an important data point for investors to monitor.

The details

According to the report, the days-to-cover ratio, which measures the number of days it would take for short sellers to cover their positions based on average daily trading volume, is currently 8.8 days. This indicates the short positions represent a significant portion of the stock's overall trading activity.

  • As of March 31st, there was short interest totaling 13,398,925 shares.
  • This represents a 22.2% increase from the March 15th total of 10,964,393 shares.

The players

Monte Rosa Therapeutics, Inc.

A biotechnology company focused on using AI and single-cell genomics to accelerate drug discovery.

Got photos? Submit your photos here. ›

The takeaway

The rise in short interest for Monte Rosa Therapeutics suggests some investors are skeptical about the company's prospects, even as it continues to advance its innovative drug discovery platform. This data point will be important to monitor as the company progresses its pipeline and seeks to demonstrate the value of its technology.